Direct thrombin inhibitors versus low molecular weight heparins as thromboprophylaxis in Staphylococcus aureus bacteraemia. A prospective randomized controlled academic single-centre feasibility study.

Trial Profile

Direct thrombin inhibitors versus low molecular weight heparins as thromboprophylaxis in Staphylococcus aureus bacteraemia. A prospective randomized controlled academic single-centre feasibility study.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Argatroban; Enoxaparin sodium
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 11 Jul 2016 Status changed from recruiting to completed.
    • 22 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top